Specifically, this was manifested as reduced neuronal degeneration, downregulation of apoptosis-related gene expression, decreased glial reactivity, and attenuated excitatory neurotoxicity.[64] These findings collectively establish both p38 MAPK and JNK pathways as promising therapeutic targets for addressing multiple pathological components of epilepsy. This evidence concerns the gene MAPK8 and epilepsy.